Valneva Provides Update on IXIARO® Supply Contract with U.S. Department of Defense
Due to the past and ongoing impact of the COVID-19 pandemic on its operations, the DoD considers its existing IXIARO supply levels sufficient to meet current needs.
- Due to the past and ongoing impact of the COVID-19 pandemic on its operations, the DoD considers its existing IXIARO supply levels sufficient to meet current needs.
- The DoD has communicated an interest in negotiating a new supply contract in 2023, once inventory returns to standard levels.
- The DoD has relied on IXIARO since 2010 to help protect personnel who are deployed to JE endemic areas, for whom JE vaccination is recommended.
- Thomas Lingelbach, President and Chief Executive Officer of Valneva, commented: We thank the DoD for their partnership and look forward to further contract negotiations in the future.